Oxford Sciences Innovation

Oxford Science Enterprises (OSE), previously known as Oxford Sciences Innovation, is a prominent investment company founded in 2015 with the mission to commercialize the cutting-edge research from the University of Oxford. OSE has raised over £850 million and invested around £775 million into over 45 core portfolio companies across three main sectors: Deep Tech, Life Sciences, and Health Tech. Notable investments include Vaccitech, the developer of the Oxford-AstraZeneca COVID-19 vaccine, Quantum Motion, and Beacon Therapeutics, which is advancing gene therapies for retinal diseases. OSE typically provides the first cheque to early-stage companies and supports them all the way to exit. Their strategy involves deep collaboration with Oxford University, leveraging the university's vast research capabilities to create transformative businesses. This partnership has resulted in over £1.4 billion in investment into university spinouts as of 2021, significantly increasing the scale and impact of Oxford's innovation ecosystem. The firm is committed to addressing some of the world's most significant challenges by supporting pioneering technologies and translating novel research into real-world applications. Their hands-on approach includes taking board seats and actively engaging with the founding teams to provide strategic guidance and operational support.